Drug Search Results
More Filters [+]

Givinostat

Alternative Names: givinostat, itf2357, itf-2357
Latest Update: 2024-11-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Italfarmaco
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Givinostat

Countries in Clinic: Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, Poland, Portugal, Serbia, Spain, United Kingdom, United States

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: Muscular Dystrophy, Duchenne|Polycythemia Vera

Phase 2: Oncology Unspecified

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DSC/11/2357/44

P2

Unknown Status

Oncology Unspecified

2029-09-30

DSC/14/2357/52

P2

Unknown Status

Muscular Dystrophy, Duchenne

2028-12-31

ULYSSES

P3

Recruiting

Muscular Dystrophy, Duchenne

2028-02-01

DSC/14/2357/50

P3

Unknown Status

Muscular Dystrophy, Duchenne

2027-12-30

Recent News Events